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our previous experience. We are currently
running a randomized study that will in-
clude a larger number of patients and will
compare VAC with other treatment modal-
ities.
With respect to their queries about
wound de´bridement in group A, 14 had
wound de´bridement, among whom 3 died
(2 patients with methicillin-resistant Staph-
ylococcus aureus sepsis and multiorgan
failure and 1 patient with pneumonia).
There was a further death in group A of a
patient who did not have wound de´bride-
ment, and the cause of death was peritoni-
tis. In group B 10 patients underwent
wound de´bridement, 1 of whom died. The
3 group B patients who did not have the
wound de´brided all survived. Moreover,
the incidence of mediastinitis was de-
scribed as a ratio, not a percentage, of 0.05
(27/491), which is equivalent to the 5%
that they calculated.
We are delighted to see Aru and Call
support the use of VAC in their letter,
although their criteria differ from ours.
However, they seem convinced that the
main treatment modality for mediastinitis
involves the use of an omental flap. We
would be grateful if they could share their
up-to-date experience, rather than the 1987
data,1 with us.
H. Luckraz, FRCS
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Reporting of clinical trials of
analgesia
To the Editor:
Ott and colleagues,1 and the editorial staff
of the Journal, deserve much credit for
carrying out and publishing a study on the
use of cyclooxygenase 2 inhibitors for
postoperative pain after coronary artery by-
pass grafting. However, the study report is
beset with serious deficiencies in the pre-
sentation of the study results, which should
be noted to avoid similar deficiencies in
what I hope will be future publications of
studies on postoperative pain relief.
Ott and colleagues1 commendably
sought to provide a risk-benefit assessment
of the use of parecoxib and valdecoxib in
the post–coronary artery bypass grafting
setting by reporting on both the degree of
pain relief and differences in adverse ef-
fects associated with the study drugs rela-
tive to the control group. The first issue is
the choice of primary outcome measure:
amount of reduction in morphine consump-
tion administered by a patient-controlled
analgesia (PCA) pump. Ott and colleagues1
reported an overall reduction of morphine
consumption of approximately 20% in the
parecoxib/valdecoxib group relative to the
placebo group. Although this may indicate
a statistically significant analgesic effect,
especially in light of the hints provided
later about the secondary analgesic efficacy
measures, the article did not discuss
whether this degree of opioid sparing was
clinically meaningful in this population. As
has been discussed at length in multiple
recent US Food and Drug Administration
Advisory Committee meetings, opioid
sparing alone does not necessarily imply
clinical benefit. Clinical benefit of opioid
sparing must be demonstrated directly, for
example by showing a reduction in opioid-
related side effects. In this study Ott and
colleagues1 appropriately reported relative
side effects in the two treatment groups.
One would hope to see a reduction in typ-
ical opioid side effects, such as nausea,
vomiting, dizziness, sedation, fatigue, and
constipation; however, these were numeri-
cally about the same in the two groups,
with the possible exceptions of dizziness
(higher in the control group) and nausea
(higher in the cyclooxygenase 2 inhibitor
group). Thus one cannot conclude that
there was clinically meaningful benefit of
the study drugs according to the primary
outcome measure of the study.
Of course, in studying an analgesic the
critical issue is whether pain control is im-
proved. Although some have argued that it
is unrealistic to expect reductions in pain
intensity when both treatment and control
groups have access to morphine PCA, in
fact multiple published studies of nonopi-
oid analgesics versus placebo in the setting
of PCA have succeeded in demonstrating
pain reduction. Unfortunately, Ott and col-
leagues1 did not provide any interpretable
pain data, which is inexcusable in a study of
an analgesic for postoperative pain. They did
provide data on the “peak pain intensity dif-
ference,” defined as the “difference between
maximum daily sternotomy pain and pre-
treatment sternotomy pain” calculated for
each day of treatment. Given that the study
drugs were administered twice a day, and that
the pretreatment pain scores are not pre-
sented, the meaning of this outcome measure
is unclear. Furthermore, the single figure in
which these data are presented suggests that
the difference between active drug and pla-
cebo was less than 1 unit on a 4-point pain
intensity scale, a difference of uncertain clin-
ical meaningfulness.
Ott and colleagues1 did obtain data on
various subscales of the Brief Pain Inven-
tory, but they chose not to present the data.
Instead, they indicated that differences in
several of these subscales between groups
had reached statistical significance, which
does not inform the reader about the mag-
nitude of potential clinical benefit. Al-
though the small differences in patient and
physician global assessments of study drug
went in the hoped-for direction, global as-
sessments are not a direct measure of pain.
This study report presented a thorough
discussion of the disturbing safety issues
associated with the cyclooxygenase 2 in-
hibitors; however, the data presented do
not justify the conclusion that “the pare-
coxib/valdecoxib regimen demonstrated
superiority for pain relief over an aggres-
sive therapeutic regimen supplemented
with PCA.” Future reports of analgesic
clinical trials should include the specific
pain data obtained, not just P values, so
that readers can decide the clinical mean-
ingfulness of any claimed benefits. This
point should be noted by both authors and
by journals, who should both be encour-
aged to continue to foster research on post-
operative analgesia.
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